Loading…
Employees: 191
Size CorMedix (CRMD) is a United States Health Care company (Biotechnology) with a market value of $415M, the 2835th largest of 3,117 United States companies the cockpit tracks. Shares closed at $5.32 on 6 Nov 2026.
Performance Over six months the shares fell 32.8%, against -18.4% for the median peer and -1.1% for the United States market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 280.5% over the last twelve months (peer median +12.9%); the operating margin is 47.0% (peer median -10.1%).
Valuation It trades at 0.7× enterprise value to sales against a peer median of 5.8× (cheapest of 17).
Capital Return on invested capital runs 38.7 points above its cost of capital (10.5% WACC).
Short interest Short interest is 18.8% of the free float (15 Oct 2026).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $462M | $312M | $43.5M | $0 | $65,408 |
| Revenue growth | — | +617% | — | -100% | — |
| Gross profit | $383M | $276M | $40.3M | -$205,562 | -$147,364 |
| EBITDA | $253M | $165M | -$21.9M | -$48.8M | -$30.4M |
| Net income | $187M | $163M | -$17.9M | -$46.3M | -$29.7M |
| Free cash flow | $250M | $173M | -$50.7M | -$38.7M | -$24.6M |
| Capital expenditure | $3.52M | $2.26M | $115,730 | $327,300 | $219,360 |
| Total debt | $145M | $149M | $517,013 | $667,632 | $802,433 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CRMD | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.3% | -9.6% | 3rd lowest of 21 |
| 6-month return | -32.8% | -18.4% | 7th lowest of 20 |
| Distance from 52-week high | -59.1% | -44.7% | 6th lowest of 21 |
| Revenue growth (TTM) | +280.5% | +12.9% | 3rd highest of 18 |
| Operating margin | 47.0% | -10.1% | 2nd highest of 18 |
| EV / Sales | 0.7× | 5.8× | cheapest of 17 |
| ROIC minus cost of capital | +38.7 pp | -9.0 pp | 3rd highest of 16 |
| EV / EBITDA | 1.2× | 17.0× | cheapest of 5 |
| Net debt / EBITDA | -0.4× | -1.8× | most indebted of 6 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 4.2× | 53.3% | +37.6% |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | 10.7× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | 6.4× | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 12.7× | 5.8% | +70.5% |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | 5.9× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | 12.1× | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |